Medallion Wealth Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Medallion Wealth Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79	Buy	+1	New	+$75	﹤0.01%	1154

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Medallion Wealth Advisors's IONS Position: Q2 2026 in Review

Medallion Wealth Advisors opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 1 share worth $79. The stake represents ﹤0.01% of the portfolio and ranks #1154 among its holdings.

513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Medallion Wealth Advisors held 1 share of Ionis Pharmaceuticals worth $79 as of Q2 2026.
Ionis Pharmaceuticals was a new Medallion Wealth Advisors position in Q2 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #1154 holding.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.